Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates

Gregory A. Eschenauer, M. Hong Nguyen, Shmuel Shoham, Jose Antonio Vazquez, Arthur J. Morris, William A. Pasculle, Christine J. Kubin, Kenneth P. Klinker, Peggy L. Carver, Kimberly E. Hanson, Sharon Chen, Simon W. Lam, Brian A. Potoski, Lloyd G. Clarke, Ryan K. Shields, Cornelius J. Clancy

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Reference broth microdilution methods of Candida echinocandin susceptibility testing are limited by interlaboratory variability in caspofungin MICs. Recently revised Clinical and Laboratory Standards Institute (CLSI) breakpoint MICs for echinocandin nonsusceptibility may not be valid for commercial tests employed in hospital laboratories. Indeed, there are limited echinocandin susceptibility testing data from hospital laboratories. We conducted a multicenter retrospective study of 9 U.S., Australian, and New Zealand hospitals that routinely tested Candida bloodstream isolates for echinocandin susceptibility from 2005 to 2013. Eight hospitals used Sensititre YeastOne assays. The Candida spp. were C. albicans (n = 1,067), C. glabrata (n = 911), C. parapsilosis (n = 476), C. tropicalis (n = 185), C. krusei (n = 104), and others (n = 154). Resistance and intermediate rates were ≤1.4% and ≤3%, respectively, for each echinocandin against C. albicans, C. parapsilosis, and C. tropicalis. Resistance rates among C. glabrata and C. krusei isolates were ≤7.5% and ≤5.6%, respectively. Caspofungin intermediate rates among C. glabrata and C. krusei isolates were 17.8% and 46.5%, respectively, compared to ≤4.3% and ≤4.4% for other echinocandins. Using CLSI breakpoints, 18% and 19% of C. glabrata isolates were anidulafungin susceptible/caspofungin nonsusceptible and micafungin susceptible/caspofungin nonsusceptible, respectively; similar discrepancies were observed for 38% and 39% of C. krusei isolates. If only YeastOne data were considered, interhospital modal MIC variability was low (within 2 doubling dilutions for each agent). In conclusion, YeastOne assays employed in hospitals may reduce the interlaboratory variability in caspofungin MICs against Candida species that are observed between reference laboratories using CLSI broth microdilution methods. The significance of classifying isolates as caspofungin intermediate and anidulafungin/micafungin susceptible will require clarification in future studies.

Original languageEnglish (US)
Pages (from-to)1897-1906
Number of pages10
JournalAntimicrobial Agents and Chemotherapy
Volume58
Issue number4
DOIs
StatePublished - Jan 1 2014

Fingerprint

caspofungin
Echinocandins
Candida
Multicenter Studies
anidulafungin
Hospital Laboratories
New Zealand
Retrospective Studies

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates. / Eschenauer, Gregory A.; Nguyen, M. Hong; Shoham, Shmuel; Vazquez, Jose Antonio; Morris, Arthur J.; Pasculle, William A.; Kubin, Christine J.; Klinker, Kenneth P.; Carver, Peggy L.; Hanson, Kimberly E.; Chen, Sharon; Lam, Simon W.; Potoski, Brian A.; Clarke, Lloyd G.; Shields, Ryan K.; Clancy, Cornelius J.

In: Antimicrobial Agents and Chemotherapy, Vol. 58, No. 4, 01.01.2014, p. 1897-1906.

Research output: Contribution to journalArticle

Eschenauer, GA, Nguyen, MH, Shoham, S, Vazquez, JA, Morris, AJ, Pasculle, WA, Kubin, CJ, Klinker, KP, Carver, PL, Hanson, KE, Chen, S, Lam, SW, Potoski, BA, Clarke, LG, Shields, RK & Clancy, CJ 2014, 'Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates', Antimicrobial Agents and Chemotherapy, vol. 58, no. 4, pp. 1897-1906. https://doi.org/10.1128/AAC.02163-13
Eschenauer, Gregory A. ; Nguyen, M. Hong ; Shoham, Shmuel ; Vazquez, Jose Antonio ; Morris, Arthur J. ; Pasculle, William A. ; Kubin, Christine J. ; Klinker, Kenneth P. ; Carver, Peggy L. ; Hanson, Kimberly E. ; Chen, Sharon ; Lam, Simon W. ; Potoski, Brian A. ; Clarke, Lloyd G. ; Shields, Ryan K. ; Clancy, Cornelius J. / Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates. In: Antimicrobial Agents and Chemotherapy. 2014 ; Vol. 58, No. 4. pp. 1897-1906.
@article{c8c87552fdba4d2b9e6e8eb6f3f49942,
title = "Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates",
abstract = "Reference broth microdilution methods of Candida echinocandin susceptibility testing are limited by interlaboratory variability in caspofungin MICs. Recently revised Clinical and Laboratory Standards Institute (CLSI) breakpoint MICs for echinocandin nonsusceptibility may not be valid for commercial tests employed in hospital laboratories. Indeed, there are limited echinocandin susceptibility testing data from hospital laboratories. We conducted a multicenter retrospective study of 9 U.S., Australian, and New Zealand hospitals that routinely tested Candida bloodstream isolates for echinocandin susceptibility from 2005 to 2013. Eight hospitals used Sensititre YeastOne assays. The Candida spp. were C. albicans (n = 1,067), C. glabrata (n = 911), C. parapsilosis (n = 476), C. tropicalis (n = 185), C. krusei (n = 104), and others (n = 154). Resistance and intermediate rates were ≤1.4{\%} and ≤3{\%}, respectively, for each echinocandin against C. albicans, C. parapsilosis, and C. tropicalis. Resistance rates among C. glabrata and C. krusei isolates were ≤7.5{\%} and ≤5.6{\%}, respectively. Caspofungin intermediate rates among C. glabrata and C. krusei isolates were 17.8{\%} and 46.5{\%}, respectively, compared to ≤4.3{\%} and ≤4.4{\%} for other echinocandins. Using CLSI breakpoints, 18{\%} and 19{\%} of C. glabrata isolates were anidulafungin susceptible/caspofungin nonsusceptible and micafungin susceptible/caspofungin nonsusceptible, respectively; similar discrepancies were observed for 38{\%} and 39{\%} of C. krusei isolates. If only YeastOne data were considered, interhospital modal MIC variability was low (within 2 doubling dilutions for each agent). In conclusion, YeastOne assays employed in hospitals may reduce the interlaboratory variability in caspofungin MICs against Candida species that are observed between reference laboratories using CLSI broth microdilution methods. The significance of classifying isolates as caspofungin intermediate and anidulafungin/micafungin susceptible will require clarification in future studies.",
author = "Eschenauer, {Gregory A.} and Nguyen, {M. Hong} and Shmuel Shoham and Vazquez, {Jose Antonio} and Morris, {Arthur J.} and Pasculle, {William A.} and Kubin, {Christine J.} and Klinker, {Kenneth P.} and Carver, {Peggy L.} and Hanson, {Kimberly E.} and Sharon Chen and Lam, {Simon W.} and Potoski, {Brian A.} and Clarke, {Lloyd G.} and Shields, {Ryan K.} and Clancy, {Cornelius J.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1128/AAC.02163-13",
language = "English (US)",
volume = "58",
pages = "1897--1906",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "4",

}

TY - JOUR

T1 - Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates

AU - Eschenauer, Gregory A.

AU - Nguyen, M. Hong

AU - Shoham, Shmuel

AU - Vazquez, Jose Antonio

AU - Morris, Arthur J.

AU - Pasculle, William A.

AU - Kubin, Christine J.

AU - Klinker, Kenneth P.

AU - Carver, Peggy L.

AU - Hanson, Kimberly E.

AU - Chen, Sharon

AU - Lam, Simon W.

AU - Potoski, Brian A.

AU - Clarke, Lloyd G.

AU - Shields, Ryan K.

AU - Clancy, Cornelius J.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Reference broth microdilution methods of Candida echinocandin susceptibility testing are limited by interlaboratory variability in caspofungin MICs. Recently revised Clinical and Laboratory Standards Institute (CLSI) breakpoint MICs for echinocandin nonsusceptibility may not be valid for commercial tests employed in hospital laboratories. Indeed, there are limited echinocandin susceptibility testing data from hospital laboratories. We conducted a multicenter retrospective study of 9 U.S., Australian, and New Zealand hospitals that routinely tested Candida bloodstream isolates for echinocandin susceptibility from 2005 to 2013. Eight hospitals used Sensititre YeastOne assays. The Candida spp. were C. albicans (n = 1,067), C. glabrata (n = 911), C. parapsilosis (n = 476), C. tropicalis (n = 185), C. krusei (n = 104), and others (n = 154). Resistance and intermediate rates were ≤1.4% and ≤3%, respectively, for each echinocandin against C. albicans, C. parapsilosis, and C. tropicalis. Resistance rates among C. glabrata and C. krusei isolates were ≤7.5% and ≤5.6%, respectively. Caspofungin intermediate rates among C. glabrata and C. krusei isolates were 17.8% and 46.5%, respectively, compared to ≤4.3% and ≤4.4% for other echinocandins. Using CLSI breakpoints, 18% and 19% of C. glabrata isolates were anidulafungin susceptible/caspofungin nonsusceptible and micafungin susceptible/caspofungin nonsusceptible, respectively; similar discrepancies were observed for 38% and 39% of C. krusei isolates. If only YeastOne data were considered, interhospital modal MIC variability was low (within 2 doubling dilutions for each agent). In conclusion, YeastOne assays employed in hospitals may reduce the interlaboratory variability in caspofungin MICs against Candida species that are observed between reference laboratories using CLSI broth microdilution methods. The significance of classifying isolates as caspofungin intermediate and anidulafungin/micafungin susceptible will require clarification in future studies.

AB - Reference broth microdilution methods of Candida echinocandin susceptibility testing are limited by interlaboratory variability in caspofungin MICs. Recently revised Clinical and Laboratory Standards Institute (CLSI) breakpoint MICs for echinocandin nonsusceptibility may not be valid for commercial tests employed in hospital laboratories. Indeed, there are limited echinocandin susceptibility testing data from hospital laboratories. We conducted a multicenter retrospective study of 9 U.S., Australian, and New Zealand hospitals that routinely tested Candida bloodstream isolates for echinocandin susceptibility from 2005 to 2013. Eight hospitals used Sensititre YeastOne assays. The Candida spp. were C. albicans (n = 1,067), C. glabrata (n = 911), C. parapsilosis (n = 476), C. tropicalis (n = 185), C. krusei (n = 104), and others (n = 154). Resistance and intermediate rates were ≤1.4% and ≤3%, respectively, for each echinocandin against C. albicans, C. parapsilosis, and C. tropicalis. Resistance rates among C. glabrata and C. krusei isolates were ≤7.5% and ≤5.6%, respectively. Caspofungin intermediate rates among C. glabrata and C. krusei isolates were 17.8% and 46.5%, respectively, compared to ≤4.3% and ≤4.4% for other echinocandins. Using CLSI breakpoints, 18% and 19% of C. glabrata isolates were anidulafungin susceptible/caspofungin nonsusceptible and micafungin susceptible/caspofungin nonsusceptible, respectively; similar discrepancies were observed for 38% and 39% of C. krusei isolates. If only YeastOne data were considered, interhospital modal MIC variability was low (within 2 doubling dilutions for each agent). In conclusion, YeastOne assays employed in hospitals may reduce the interlaboratory variability in caspofungin MICs against Candida species that are observed between reference laboratories using CLSI broth microdilution methods. The significance of classifying isolates as caspofungin intermediate and anidulafungin/micafungin susceptible will require clarification in future studies.

UR - http://www.scopus.com/inward/record.url?scp=84896994835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896994835&partnerID=8YFLogxK

U2 - 10.1128/AAC.02163-13

DO - 10.1128/AAC.02163-13

M3 - Article

VL - 58

SP - 1897

EP - 1906

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 4

ER -